Follow the Pundits
Tag: Funanc1al Edge
Balyasny Asset Management’s 2025 Scorecard: Solid Performance, Serious Machine
Balyasny Asset Management posted a strong +16.7% in 2025—but so did the market. This isn’t a story about fireworks. It’s a story about a world-class multi-strategy machine, risk control, and why institutions still pay for discipline, not just beta.
Madrigal, BeiGene, and Biotech Alpha: Inside the “Gene-ius” Kingmakers of Baker Bros. 2025
Biotech Jedi at work. Baker Bros’ 2025 victory lap shows how Madrigal, BeiGene, and ruthless conviction turned science into serious alpha.
D.E. Shaw’s 2025 Scorecard: Put on Quite a Show With AI and Quants
D.E. Shaw put on a quant-powered show in 2025 — and quietly built a private-credit fortress for what comes next.
AQR Capital’s 2025 Scorecard: From Applied Quantitative Research to Actually Quality Returns
AQR Capital’s machines finally had their year. Strong 2025 returns across quant strategies prove factors aren’t dead — they just needed faster computers.
Pershing Square Rounds Up a Strong 2025: High Conviction, Concentrated Bets — and Real Outperformance
Pershing Square’s concentrated, high-conviction strategy paid off in 2025. Fewer bets, bigger opinions — and real outperformance.
Berkshire Hathaway's 2025 Scorecard: Defensive Portfolio, Slightly Underwhelming Performance — But a Historic Transition
Berkshire played defense in 2025: record cash, cautious positioning, and the end of an era as Warren Buffett stepped aside. Solid, sober, and very Berkshire.
Elliott’s 2025 Paradox: Why the Parachute Cost Them the Party
While Wall Street partied through an AI-fueled bull market, Elliott Management showed up wearing a parachute. The result was underperformance — by design. Here’s why Paul Singer’s 2025 wasn’t a failure, but a strategic bet on what comes next.
Principles of Prosperity: How Bridgewater’s AI-Driven “Machine” Built a Fortress in 2025
After years of skepticism, Bridgewater roared back in 2025. Pure Alpha surged, All Weather delivered, and Ray Dalio’s machine pivoted hard into U.S. equities and AI infrastructure. Fortress rebuilt — with a few cracks worth watching.
Revisiting The Case of CRISPR Therapeutics: Still Crisp, Still Risky, Still Dangerously Alluring
CRISPR Therapeutics (CRSP) has the first widely approved CRISPR-based therapy, huge insider buying near today’s price, and institutions (including ARK) deep in the name — while shorts pile on. Crisp setup, risky execution, dangerously alluring upside. 🧬🎯
Funds Still Love Meta Platforms — Should Retail Add on Dips?
Funds remain heavily invested in Meta Platforms as AI boosts ads and cash flow — but at today’s price, patience may still pay off.